Natera, Inc. (NTRA) stock
NTRANasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 10/30152% above fair value
$319.09−3.85 (-1.19%)
Close on Nov 13, 2026Market cap $46.00BP/E –Yield –
Natera ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Natera's ebitda for the twelve months ending Sep 30, 2026 was -$201.78M. For fiscal 2025 it was -$268.15M. The highest annual figure on record is $5.81M in fiscal 2014.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$268.15M | – |
| FY2024 | Dec 31, 2024 | -$191.33M | – |
| FY2023 | Dec 31, 2023 | -$422.15M | – |
| FY2022 | Dec 31, 2022 | -$524.34M | – |
| FY2021 | Dec 31, 2021 | -$456.92M | – |
| FY2020 | Dec 31, 2020 | -$207.66M | – |
| FY2019 | Dec 31, 2019 | -$108.56M | – |
| FY2018 | Dec 31, 2018 | -$107.13M | – |
| FY2017 | Dec 31, 2017 | -$128.20M | – |
| FY2016 | Dec 31, 2016 | -$94.87M | – |
| FY2015 | Dec 31, 2015 | -$54.30M | -1034.2% |
| FY2014 | Dec 31, 2014 | $5.81M | – |
| FY2013 | Dec 31, 2013 | -$22.74M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$52.06M | – |
| Q2 FY2026 | Jun 30, 2026 | -$60.31M | – |
| Q1 FY2026 | Mar 31, 2026 | -$79.00M | – |
| Q4 FY2025 | Dec 31, 2025 | -$10.41M | – |
| Q3 FY2025 | Sep 30, 2025 | -$87.28M | – |
| Q2 FY2025 | Jun 30, 2025 | -$100.51M | – |
| Q1 FY2025 | Mar 31, 2025 | -$69.94M | – |
| Q4 FY2024 | Dec 31, 2024 | -$56.95M | – |
| Q3 FY2024 | Sep 30, 2024 | -$31.14M | – |
| Q2 FY2024 | Jun 30, 2024 | -$35.99M | – |
| Q1 FY2024 | Mar 31, 2024 | -$67.25M | – |
| Q4 FY2023 | Dec 31, 2023 | -$77.63M | – |
| Q3 FY2023 | Sep 30, 2023 | -$104.00M | – |
| Q2 FY2023 | Jun 30, 2023 | -$107.30M | – |
| Q1 FY2023 | Mar 31, 2023 | -$133.22M | – |
| Q4 FY2022 | Dec 31, 2022 | -$137.84M | – |
| Q3 FY2022 | Sep 30, 2022 | -$113.91M | – |
| Q2 FY2022 | Jun 30, 2022 | -$138.46M | – |
| Q1 FY2022 | Mar 31, 2022 | -$134.13M | – |
| Q4 FY2021 | Dec 31, 2021 | -$136.67M | – |
| Q3 FY2021 | Sep 30, 2021 | -$147.20M | – |
| Q2 FY2021 | Jun 30, 2021 | -$112.58M | – |
| Q1 FY2021 | Mar 31, 2021 | -$60.47M | – |
| Q4 FY2020 | Dec 31, 2020 | -$71.57M | – |
| Q3 FY2020 | Sep 30, 2020 | -$53.60M | – |
| Q2 FY2020 | Jun 30, 2020 | -$49.45M | – |
| Q1 FY2020 | Mar 31, 2020 | -$33.05M | – |
| Q4 FY2019 | Dec 31, 2019 | -$33.00M | – |
| Q3 FY2019 | Sep 30, 2019 | -$15.17M | – |
| Q2 FY2019 | Jun 30, 2019 | -$24.68M | – |
| Q1 FY2019 | Mar 31, 2019 | -$29.83M | – |
| Q4 FY2018 | Dec 31, 2018 | -$27.80M | – |
| Q3 FY2018 | Sep 30, 2018 | -$25.27M | – |
| Q2 FY2018 | Jun 30, 2018 | -$25.40M | – |
| Q1 FY2018 | Mar 31, 2018 | -$28.66M | – |
| Q4 FY2017 | Dec 31, 2017 | -$44.81M | – |
| Q3 FY2017 | Sep 30, 2017 | -$24.09M | – |
| Q2 FY2017 | Jun 30, 2017 | -$26.51M | – |
| Q1 FY2017 | Mar 31, 2017 | -$32.79M | – |
| Q4 FY2016 | Dec 31, 2016 | -$40.28M | – |
See a number that looks wrong?